Organization
Analysis Group, Inc.
13 abstracts
2 posters
Abstract
Short-term risk of recurrence in patients (pts) with HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in randomized clinical trials (RCTs): A meta-analysis.Org: Analysis Group, Inc., Novartis Pharmaceuticals Corporation, University Hospital Erlangen, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Real-world monitoring and treatment patterns in von Hippel-Lindau (VHL) disease-associated central nervous system hemangioblastomas (CNS-Hb).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Analysis Group, Inc., Merck Sharp & Dohme, Merck & Co., Inc.,
Abstract
Real-world evidence of overall survival (OS) and treatment patterns of patients (pts) with testicular germ cell tumors (GCT) receiving palliative chemotherapy in the United States.Org: Memorial Sloan Kettering Cancer Center, New York, NY, BioNTech, New Kensignton, PA, Analysis Group, Inc.,
Abstract
Real-world treatment patterns and overall survival (OS) in locoregionally advanced head and neck squamous cell carcinoma (LA HNSCC) in the U.S.Org: Analysis Group, Inc., Merck & Co., Inc., Department of Medical Oncology, Dana-Farber Cancer Institute,
Abstract
Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Karmanos Cancer Institute, University of Miami Health System,
Abstract
Real-world first-line treatment patterns and outcomes in patients with locally advanced or metastatic urothelial carcinoma in the United States.Org: University of Kansas Medical Center, Department of Biostatistics & Data Science, Astellas Pharma Inc., Astellas Pharma, Inc., Analysis Group, Inc., Pfizer Inc.,
Abstract
Evaluation of persistence and adherence for oral and injectable androgen deprivation therapies (ADT) in United States (US) patients with prostate cancer (PC).Org: Michigan Institute of Urology, Pfizer Inc., Sumitomo Pharma Switzerland, Analysis Group, Inc., Sumitomo Pharma America,
Abstract
Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L).Org: Janssen Scientific Affairs, Analysis Group, Inc.,
Abstract
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction (PCR) versus next-generation sequencing (NGS) testing strategies in metastatic non-small cell lung cancer (mNSCLC).Org: University of Chicago, Janssen Scientific Affairs, Analysis Group, Inc.,
Abstract
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).Org: University Hospital Essen, University Duisburg-Essen, West German Cancer Centre (WTZ), German Cancer Consortium (DKTK), Partner Site Munich, Partner Site Essen,
Abstract
Real-world evidence study of treatment patterns and outcomes following covalent BTKi discontinuation in a contemporary cohort of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients.Org: Dana-Farber Cancer Institute, Boston Pharmaceuticals, MaaT Pharma, Analysis Group, Inc., Inc.,
Abstract
A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF UPADACITINIB VERSUS TOFACITINIB IN CSDMARD-IR PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA)Org: AbbVie Inc., North Chicago, IL, Analysis Group, Inc.,
Abstract
BIOLOGIC DISEASE-MODIFYING DRUG TREATMENT PATTERNS AND ASSOCIATED COSTS FOR RHEUMATOID ARTHRITIS PATIENTS Org: Analysis Group, Inc., Global Health Outcomes, MERCK & CO., INC, Whitehouse Station, Eli Lilly and Company,